Pharmaindustrie

Hong Kong is recruiting for its Centre for Medical Products Regulation, expected to launch by the fourth quarter of 2026, as it seeks World Health Organization recognition and aims for independent drug approvals by 2030.

25. Juni 2026 Von KI berichtet

Laurus Labs reported strong financial results for fiscal 2026, driving a 30 percent gain in its share price. Growth in contract manufacturing and a better product mix supported the performance.

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

4. Juni 2026 Von KI berichtet

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents hat Sharif Ahmed El Akhdar nach dem Investment von LVP Pharma zum nicht geschäftsführenden Vorsitzenden ernannt. Gleichzeitig wurden zwei weitere Vorstandsmitglieder berufen.

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

24. Mai 2026 Von KI berichtet

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.